ABSTRACT
The parasitic helminth Schistosoma mansoni is a potent inducer of type 2 immune responses by stimulating dendritic cells (DCs) to prime T helper 2 (Th2) responses. We previously found that S. mansoni soluble egg antigens (SEA) promote the synthesis of Prostaglandin E2 (PGE2) by DCs through ERK-dependent signaling via Dectin-1 and Dectin-2 that subsequently induces OX40L expression, licensing them for Th2 priming, yet the ligands present in SEA involved in driving this response and whether specific targeting of PGE2 synthesis by DCs could affect Th2 polarization are unknown. We here show that the ability of SEA to bind Dectin-2 and drive ERK phosphorylation, PGE2 synthesis, OX40L expression, and Th2 polarization is impaired upon cleavage of high-mannose glycans by Endoglycosidase H treatment. This identifies high-mannose glycans present on glycoproteins in SEA as important drivers of this signaling axis. Moreover, we find that OX40L expression and Th2 induction are abrogated when microsomal prostaglandin E synthase-1 (mPGES) is selectively inhibited, but not when a general COX-1/2 inhibitor is used. This shows that the de novo synthesis of PGE2 is vital for the Th2 priming function of SEA-stimulated DCs as well as points to the potential existence of other COX-dependent lipid mediators that antagonize PGE2-driven Th2 polarization. Lastly, specific PGE2 inhibition following immunization with S. mansoni eggs dampened the egg-specific Th cell response. In summary, our findings provide new insights in the molecular mechanisms underpinning Th2 induction by S. mansoni and identify druggable targets for potential control of helminth driven-Th2 responses.
Subject(s)
Dinoprostone , Lectins, C-Type , Mannose , Polysaccharides , Schistosoma mansoni , Th2 Cells , Animals , Mice , Antigens, Helminth/immunology , Dendritic Cells/immunology , Dendritic Cells/metabolism , Dinoprostone/metabolism , Lectins, C-Type/metabolism , Lectins, C-Type/immunology , Mannose/metabolism , Mannose/immunology , Mice, Inbred C57BL , Ovum/immunology , Ovum/metabolism , OX40 Ligand/metabolism , Polysaccharides/immunology , Polysaccharides/metabolism , Schistosoma mansoni/immunology , Schistosomiasis mansoni/immunology , Schistosomiasis mansoni/metabolism , Schistosomiasis mansoni/parasitology , Th2 Cells/immunology , Th2 Cells/metabolismABSTRACT
Oligomannose-coated liposomes (OMLs) comprised of dipalmitoylphosphatidylcholine, cholesterol and Man3-DPPE at a molar ratio of 1:1:0.1 and particle diameters of about 1000 nm can induce liposome-encased antigen-specific strong Th1 immunity. In this study, we evaluated the effect of particle sizes of OMLs on induction of Th1 immune responses in mice. Spleen cells obtained from mice immunized with antigen-encapsulating OMLs with 1000- and 800-nm diameters secreted remarkably high levels of IFN-γ upon in vitro stimulation. In addition, sera of mice that received these OMLs had significantly higher titers of antigen-specific IgG2a than those of IgG1, which are commonly associated with Th1 responses. In contrast, treatment with antigen-encapsulating OMLs with 400- and 200-nm diameters failed to induce IFN-γ secretion from spleen cells, although these OMLs did elicit elevation of antigen-specific IgGs. In addition, the titers of serum antigen-specific IgG2a were the same as those of IgG1 in mice that received 400-nm OMLs. Resident peritoneal mononuclear phagocytes (MNPs) treated with OMLs of diameter ≥ 600 nm secreted IL-12, which is essential for induction of Th1 immune responses, while those treated with OMLs of ≤ 400 nm failed to produce this cytokine. However, 400-nm OMLs did induce enhanced expression of MHC class II and costimulatory molecules on MNPs, similarly to OMLs of ≥ 600 nm. Taken together, these results strongly indicate that OMLs of diameter ≥ 600 nm are required to induce Th1 immune responses against OML-encased antigens, although OMLs of diameter ≤ 400 nm can activate MNPs.
Subject(s)
Liposomes/chemistry , Liposomes/immunology , Mannose/chemistry , Mannose/immunology , Th1 Cells/immunology , 1,2-Dipalmitoylphosphatidylcholine/immunology , Animals , Antigens/immunology , B7-2 Antigen/metabolism , Cytochalasin D/pharmacology , Female , Histocompatibility Antigens Class II/drug effects , Histocompatibility Antigens Class II/metabolism , Immune System , Immunoglobulin G/blood , Interferon-gamma/drug effects , Interferon-gamma/metabolism , Interleukin-12 Subunit p35/metabolism , Mice , Particle Size , Peritoneal Absorption/drug effects , Phagocytes/drug effects , Phagocytes/metabolism , Phagocytosis/drug effects , Spleen/drug effects , Spleen/metabolismABSTRACT
Parenteral administration of killed/inactivated swine influenza A virus (SwIAV) vaccine in weaned piglets provides variable levels of immunity due to the presence of preexisting virus specific maternal derived antibodies (MDA). To overcome the effect of MDA on SwIAV vaccine in piglets, we developed an intranasal deliverable killed SwIAV antigen (KAg) encapsulated chitosan nanoparticles called chitosan-based NPs encapsulating KAg (CS NPs-KAg) vaccine. Further, to target the candidate vaccine to dendritic cells and macrophages which express mannose receptor, we conjugated mannose to chitosan (mCS) and formulated KAg encapsulated mCS nanoparticles called mannosylated chitosan-based NPs encapsulating KAg (mCS NPs-KAg) vaccine. In MDA-positive piglets, prime-boost intranasal inoculation of mCS NPs-KAg vaccine elicited enhanced homologous (H1N2-OH10), heterologous (H1N1-OH7), and heterosubtypic (H3N2-OH4) influenza virus-specific secretory IgA (sIgA) antibody response in nasal passage compared to CS NPs-KAg vaccinates. In vaccinated upon challenged with a heterologous SwIAV H1N1, both mCS NPs-KAg and CS NPs-KAg vaccinates augmented H1N2-OH10, H1N1-OH7, and H3N2-OH4 virus-specific sIgA antibody responses in nasal swab, lung lysate, and bronchoalveolar lavage (BAL) fluid; and IgG antibody levels in lung lysate and BAL fluid samples. Whereas, the multivalent commercial inactivated SwIAV vaccine delivered intramuscularly increased serum IgG antibody response. In mCS NPs-KAg and CS NPs-KAg vaccinates increased H1N2-OH10 but not H1N1-OH7 and H3N2-OH4-specific serum hemagglutination inhibition titers were observed. Additionally, mCS NPs-KAg vaccine increased specific recall lymphocyte proliferation and cytokines IL-4, IL-10, and IFNγ gene expression compared to CS NPs-KAg and commercial SwIAV vaccinates in tracheobronchial lymph nodes. Consistent with the immune response both mCS NPs-KAg and CS NPs-KAg vaccinates cleared the challenge H1N1-OH7 virus load in upper and lower respiratory tract more efficiently when compared to commercial vaccine. The virus clearance was associated with reduced gross lung lesions. Overall, mCS NP-KAg vaccine intranasal immunization in MDA-positive pigs induced a robust cross-reactive immunity and offered protection against influenza virus.
Subject(s)
Chitosan/immunology , Immunity/immunology , Influenza Vaccines/immunology , Mannose/immunology , Orthomyxoviridae Infections/immunology , Swine Diseases/immunology , Animals , Antibodies, Viral/immunology , Cells, Cultured , Chitosan/metabolism , Dogs , Female , Immunity/drug effects , Influenza Vaccines/administration & dosage , Madin Darby Canine Kidney Cells , Mannose/metabolism , Nanoparticles/administration & dosage , Orthomyxoviridae Infections/prevention & control , Orthomyxoviridae Infections/virology , Pregnancy , Swine , Swine Diseases/prevention & control , Swine Diseases/virology , Vaccination/methods , Vaccines, Inactivated/administration & dosage , Vaccines, Inactivated/immunologyABSTRACT
We found that the extract of the body wall of the sea urchin, Pseudocentrotus depressus, agglutinate Escherichia coli and is inhibited by mannose. A mannose-binding protein of 22 kDa was purified via affinity chromatography using mannose-agarose. Amino acid sequences obtained by Edman degradation and liquid chromatography quadrupole time-of-flight mass spectrometry followed by de novo sequencing suggested that the protein is a C-type lectin. Products of PCR with a degenerate primer pair and of RACE PCR for the cDNA of the 22 kDa protein were sequenced and produced two full-length cDNA sequences encoding C-type lectins. These two lectins, named P. depressus mannose-binding C-type lectin (PdMBCL) 1 and 2 are composed of 187 and 189 amino acid residues, including signal peptides, respectively, and share 86% identity in their mature form. PdMBCLs agglutinated Lactococcus garvieae, a Gram-positive fish pathogen. Reverse transcription PCR showed that both the genes for the PdMBCLs were expressed in the body wall and in other tissues. Furthermore, the lectins were detected from a rinse of the body surface. Taken together, the present study showed that PdMBCLs function as anti-microbial agents on the body surface of P. depressus.
Subject(s)
Escherichia coli/immunology , Immunity, Innate/immunology , Lactococcus/immunology , Lectins, C-Type/immunology , Mannose/immunology , Sea Urchins/immunology , Amino Acid Sequence , Animals , Base Sequence , Escherichia coli/physiology , Gene Expression/immunology , Gene Expression Profiling/methods , Host-Pathogen Interactions/immunology , Immunity, Innate/genetics , Lactococcus/physiology , Lectins, C-Type/genetics , Lectins, C-Type/metabolism , Mannose/metabolism , Phylogeny , Sea Urchins/genetics , Sea Urchins/microbiology , Sequence Analysis, DNA/methods , Sequence Homology, Amino AcidABSTRACT
Peritoneal dialysis (PD) employs hypertonic glucose to remove excess water and uremic waste. Peritoneal membrane failure limits its long-term use. T-cell cytokines promote this decline. T-cell differentiation is critically determined by the microenvironment. We here study how PD-range hypertonic glucose regulates T-cell polarization and IL-17 production. In the human peritoneal cavity, CD3+ cell numbers increased in PD. Single cell RNA sequencing detected expression of T helper (Th) 17 signature genes RORC and IL23R. In vitro, PD-range glucose stimulated spontaneous and amplified cytokine-induced Th17 polarization. Osmotic controls l-glucose and d-mannose demonstrate that induction of IL-17A is a substance-independent, tonicity dose-dependent process. PD-range glucose upregulated glycolysis and increased the proportion of dysfunctional mitochondria. Blockade of reactive-oxygen species (ROS) prevented IL-17A induction in response to PD-range glucose. Peritoneal mesothelium cultured with IL-17A or IL17F produced pro-inflammatory cytokines IL-6, CCL2, and CX3CL1. In PD patients, peritoneal IL-17A positively correlated with CX3CL1 concentrations. PD-range glucose-stimulated, but neither identically treated Il17a-/- Il17f-/- nor T cells cultured with the ROS scavenger N-acetylcysteine enhanced mesothelial CX3CL1 expression. Our data delineate PD-range hypertonic glucose as a novel inducer of Th17 polarization in a mitochondrial-ROS-dependent manner. Modulation of tonicity-mediated effects of PD solutions may improve membrane survival.
Subject(s)
Epithelium/immunology , Glucose/immunology , Inflammation/immunology , Interleukin-17/immunology , Peritoneum/immunology , Th17 Cells/immunology , Animals , Cells, Cultured , Chemokine CCL2/immunology , Chemokine CXCL1/immunology , Female , Humans , Interleukin-6/immunology , Male , Mannose/immunology , Mice , Mice, Inbred C57BL , Middle Aged , Mitochondria/immunology , Peritoneal Dialysis/methods , Reactive Oxygen Species/immunology , Up-Regulation/immunologyABSTRACT
Ovalbumin (OVA) is one of the major food allergens in hen eggs. In this work, it was demonstrated that glycation with d-glucose and its epimers, including d-mannose, d-allose, d-galactose, and l-idose, could effectively attenuate the IgG/IgE binding of OVA, which was attributed to the covalent masking by sugars and to its structural changes. The glycation sites were determined, and their average degree of substitution was found using liquid chromatography coupled with high-resolution mass spectrometry. Fluctuations in OVA conformation were monitored by conventional spectrometry. Compared to those of OVA-Man and OVA-Glu, OVA-All, OVA-Gal, and OVA-Ido showed a higher glycation extent, and the alterations on their steric layouts were more drastic, suggesting that the configuration of hydroxyl groups at positions C-3, C-4, and C-5 in sugars might be important for the glycation reactivity; as such, their capabilities in binding with IgG/IgE decreased more significantly. Attempts were made to provide valuable information for in-depth understanding of the differences in biochemical functionality among epimeric sugars. These insights would be helpful for designing sweetened food products with a desirable level of safety.
Subject(s)
Egg Hypersensitivity/immunology , Immunoglobulin E/immunology , Immunoglobulin G/immunology , Ovalbumin/immunology , Animals , Chickens , Eggs/analysis , Galactose/chemistry , Galactose/immunology , Glucose/chemistry , Glucose/immunology , Glycosylation , Hexoses/chemistry , Hexoses/immunology , Humans , Mannose/chemistry , Mannose/immunology , Mass Spectrometry , Ovalbumin/chemistryABSTRACT
Heterobothrium okamotoi, a monogenean gill parasite, exhibits high host specificity for the tiger puffer, Takifugu rubripes, and it has been experimentally verified that the parasite cannot colonize either closely related species such as the grass puffer Takifugu niphobles or distantly related fish such as the red seabream Pagrus major. Previously, we demonstrated in T. rubripes that immunoglobulin M (IgM) with d-mannose affinity induced deciliation of the oncomiracidia, the first step of parasitism, indicating that the parasite utilizes the molecule as a receptor for infection. In the present study, we purified mannose-specific IgM from 2 nonhost species, T. niphobles and P. major, by affinity and gel-filtration chromatography techniques and compared their deciliation-inducing activity against H. okamotoi oncomiracidia. The IgM of the former showed activity, whereas the latter had no effect, suggesting that in addition to d-mannose-binding ability, the crystallizable fragment domain of IgM, which is not part of the antigen-binding domain, plays an important role in host recognition by the oncomiracidia, such as direct binding to the parasites. It also suggests that the host specificity of H. okamotoi is relatively low upon initial recognition, and the specificity is established by exclusion in nonhosts during a later stage.
Subject(s)
Ectoparasitic Infestations/veterinary , Fish Diseases/parasitology , Immunoglobulin M/physiology , Mannose/immunology , Platyhelminths/immunology , Takifugu/parasitology , Amino Acid Sequence , Animals , Blotting, Western , Cilia/immunology , Cloning, Molecular , DNA, Complementary/genetics , DNA, Complementary/immunology , Ectoparasitic Infestations/immunology , Ectoparasitic Infestations/parasitology , Electrophoresis, Polyacrylamide Gel , Fish Diseases/immunology , Gene Expression , Gills/parasitology , Host Specificity , Hydrogen-Ion Concentration , Immunoglobulin M/blood , Immunoglobulin M/genetics , Immunoglobulin M/isolation & purification , Mucous Membrane/chemistry , Mucous Membrane/immunology , Mucous Membrane/parasitology , Platyhelminths/pathogenicity , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization , Takifugu/immunology , Trematode Infections/immunology , Trematode Infections/parasitology , Trematode Infections/veterinaryABSTRACT
Brucellosis is a worldwide bacterial zoonosis disease. Live attenuated Brucella vaccines have several drawbacks. Thus development of a safe and effective vaccine for brucellosis is a concern of many scientists. FliC protein contributes in virulence of Brucella; hence, it is a promising target for brucellosis vaccine. In this study, Mannosylated Chitosan Nanoparticles (MCN) loaded with FliC protein were synthesized as a targeted vaccine delivery system. The immunogenicity and protective efficacy of FliC and FliC-MCN against Brucella infection were evaluated in BALB/c mice. After cloning, expression and purification, FliC protein was loaded on MCN. The particle size, loading efficiency and in vitro release of the NPs were determined. Our investigation revealed that FliC and FliC-MCN could significantly increase specific IgG response (higher IgG2a titers). Besides, spleen cells from immunized mice produced high level of IFN-γ and IL-2 and low level IL-10 cytokines. Immunization with FliC and FliC-MCN conferred significant degree of protection against B. melitensis 16 M and B. abortus 544 infections. Overall these results indicate that FliC protein would be a novel potential antigen candidate for the development of a subunit vaccine against B. melitensis and B. abortus. Moreover, MCN could be used as an adjuvant and targeted vaccine delivery system.
Subject(s)
Antigens, Bacterial , Brucella Vaccine , Brucella abortus/immunology , Brucella melitensis/immunology , Brucellosis/prevention & control , Chitosan , Mannose , Nanoparticles/chemistry , Animals , Antigens, Bacterial/chemistry , Antigens, Bacterial/immunology , Antigens, Bacterial/pharmacology , Antineoplastic Combined Chemotherapy Protocols , Brucella Vaccine/chemistry , Brucella Vaccine/immunology , Brucella Vaccine/pharmacology , Brucellosis/immunology , Brucellosis/pathology , Chitosan/chemistry , Chitosan/immunology , Chitosan/pharmacology , Cisplatin , Female , Ifosfamide , Mannose/chemistry , Mannose/immunology , Mannose/pharmacology , Mice, Inbred BALB C , MitomycinABSTRACT
Olive pollen is one of the most important causes of respiratory allergy, with Ole e 1 being the most clinically relevant sensitizing allergen. Peptide-based vaccines represent promising therapeutic approaches, but the use of adjuvants is required to strengthen the weak immunogenicity of small peptides. We propose the use of dendrimeric scaffolds conjugated to the T cell immunodominant epitope of Ole e 1 (OE109-130) for the development of novel vaccines against olive pollen allergy. Four dendrimeric scaffolds containing an ester/ether with nine mannoses, an ester succinimidyl linker with nine N-acetyl-glucosamine units or nine ethylene glycol units conjugated to OE109-130 peptide were designed, and their cytotoxicity, internalization pattern, and immunomodulatory properties were analyzed in vitro. None of the dendrimers exhibited cytotoxicity in humanized rat basophil (RBL-2H3), human bronchial epithelial Calu-3, and human mast LAD2 cell lines. Confocal images indicated that mannosylated glycodendropeptides exhibited lower colocalization with a lysosomal marker. Moreover, mannosylated glycodendropeptides showed higher transport tendency through the epithelial barrier formed by Calu-3 cells cultured at the air-liquid interface. Finally, mannosylated glycodendropeptides promoted Treg and IL10+Treg proliferation and IL-10 secretion by peripheral blood mononuclear cells from allergic patients. Mannosylated dendrimers conjugated with OE109-130 peptide from Ole e 1 have been identified as suitable candidates for the development of novel vaccines of olive pollen allergy.
Subject(s)
Antigens, Plant/chemistry , Dendrimers/chemistry , Mannose/immunology , Olea/chemistry , Olea/immunology , Peptides/immunology , Plant Proteins/chemistry , Pollen/immunology , Rhinitis, Allergic, Seasonal/prevention & control , Vaccines, Subunit/immunology , Adjuvants, Immunologic/chemistry , Animals , Antigens, Plant/immunology , Cell Line, Tumor , Cell Survival/immunology , Cytokines/analysis , Cytokines/metabolism , Epithelial Cells/immunology , Epithelial Cells/metabolism , Epitopes, T-Lymphocyte/chemistry , Epitopes, T-Lymphocyte/immunology , Humans , Immunogenicity, Vaccine , Mannose/chemistry , Peptides/chemistry , Plant Proteins/immunology , Rats , Respiratory Mucosa/immunology , Respiratory Mucosa/metabolism , Rhinitis, Allergic, Seasonal/blood , Rhinitis, Allergic, Seasonal/immunology , T-Lymphocytes/immunology , T-Lymphocytes/metabolismABSTRACT
An effective prophylactic HIV-1 vaccine is essential in order to contain the HIV/AIDS global pandemic. The discovery of different broadly neutralizing antibodies (bnAbs) in the last decades has enabled the characterization of several minimal epitopes on the HIV envelope (Env) spike, including glycan-dependent fragments. Herein, we provide a brief overview of the progress made on the development of synthetic carbohydrate-based epitope mimics for the elicitation of bnAbs directed to certain regions on Env gp120 protein: the outer domain high-mannose cluster and the variable loops V1V2 and V3. We focus on the design, synthesis and biological evaluation of minimal immunogens and discuss key aspects towards the development of a successful protective vaccine against HIV-1.
Subject(s)
AIDS Vaccines/administration & dosage , Antibodies, Viral/immunology , Broadly Neutralizing Antibodies/immunology , HIV Infections/prevention & control , HIV-1/immunology , AIDS Vaccines/chemical synthesis , AIDS Vaccines/immunology , Animals , Antibodies, Viral/metabolism , Broadly Neutralizing Antibodies/metabolism , Disease Models, Animal , Drug Design , Epitopes/immunology , Epitopes/metabolism , Epitopes/ultrastructure , HIV Envelope Protein gp120/immunology , HIV Envelope Protein gp120/metabolism , HIV Envelope Protein gp120/ultrastructure , HIV Infections/immunology , HIV Infections/virology , HIV-1/ultrastructure , Humans , Immunogenicity, Vaccine , Macaca , Mannose/chemistry , Mannose/immunology , Protein Domains/immunology , Vaccines, Synthetic/administration & dosage , Vaccines, Synthetic/chemistry , Vaccines, Synthetic/immunologyABSTRACT
A novel homogeneous polysaccharide (CMP-III) was extracted and purified from C. militaris. Structural characterization revealed that CMP-III had an average molecular weight of 4.796 × 104 kDa and consisted of glucose, mannose and galactose with the molar ratio of 8.09:1.00:0.25. The main linkage types of CMP-III consisted of 1 â 4)-α-D-Glc (70.08%), 1 â 4,6)-α-D-Man (9.59%), 1â)-α-D-Man (10.79%) and 1 â 2,6)-α-D-Gal (3.93%) based on methylation and NMR analysis. The immunomodulatory assay indicated that CMP-III significantly promoted macrophage phagocytosis and secretion of NO, TNF-α and IL-6. Further study suggested that macrophage activated by CMP-III involved mitogen-activated protein kinases (MAPKs) and nuclear factor kappa-B (NF-κB) signaling pathways. Overall, these results suggested that CMP-III could be developed as a potent immunomodulatory agent for use in functional foods and dietary supplements.
Subject(s)
Cordyceps/chemistry , Cordyceps/immunology , Polysaccharides/chemistry , Polysaccharides/immunology , Animals , Cell Line , Dietary Carbohydrates/chemical synthesis , Dietary Carbohydrates/immunology , Galactose/chemistry , Galactose/immunology , Immunologic Factors/immunology , Macrophages/immunology , Mannose/immunology , Mice , Mitogen-Activated Protein Kinases/immunology , Molecular Weight , NF-kappa B/immunology , Phagocytosis/immunology , RAW 264.7 Cells , Tumor Necrosis Factor-alpha/immunologyABSTRACT
A series of broadly neutralizing antibodies called PGT have been shown to be bound directly to human immunodeficiency virus type-1 via high mannose glycans on glycoprotein gp120. Despite the sequence similarities of amino acids of the antibodies, their affinities to the glycan differ. Glycan-antibody interactions among these antibodies are systematically compared with quantum chemical fragment molecular orbital calculations and molecular dynamics simulations. The differences among structural stability of the glycan in the active site of the complexes and total interaction energies as well as binding free energies between the glycan and antibodies agree well with the experimentally shown affinities of the glycan to the antibodies. The terminal saccharide, Man D3, is structurally stable and responsible for the glycan-antibody binding through electrostatic and dispersion interactions. The structural stability of nonterminal saccharides such as Man 4 or Man C plays substantial roles in the interaction via direct hydrogen bonds. © 2019 Wiley Periodicals, Inc.
Subject(s)
Antibodies, Neutralizing/immunology , HIV-1/immunology , Mannose/immunology , Molecular Dynamics Simulation , Polysaccharides/immunology , Quantum Theory , Antibodies, Neutralizing/chemistry , HIV-1/chemistry , Humans , Mannose/chemistry , Polysaccharides/chemistryABSTRACT
Inflammatory bowel disease (IBD) is a chronic, non-specific, inflammatory gastrointestinal disease that mainly consists of Crohn's disease and ulcerative colitis. However, the aetiology and pathogenesis of IBD are still unclear. B10 (IL-10 producing regulatory B) cells, a subset of regulatory B cells, are known to contribute to intestinal homeostasis and the aberrant frequency of B10 cells is associated with IBD. We have recently reported that B10 cells can be induced by ManLAM (mannose-capped lipoarabinomannan), a major cell-wall lipoglycan of M tb (Mycobacterium tuberculosis). In the current study, the ManLAM-induced B10 cells were adoptively transferred into IL(interleukin)-10-/- mice and the roles of ManLAM-induced B10 cells were investigated in DSS (dextran sodium sulphate)-induced IBD model. ManLAM-induced B10 cells decrease colitis severity in the mice. The B10 cells downregulate Th1 polarization in spleen and MLNs (mesenteric lymph nodes) of DSS-treated mice. These results suggest that IL-10 production by ManLAM-treated B cells contributes to keeping the balance between CD4+ T cell subsets and protect mice from DSS-induced IBD.
Subject(s)
B-Lymphocytes, Regulatory/immunology , Inflammatory Bowel Diseases/immunology , Interleukin-10/metabolism , Lipopolysaccharides/metabolism , Mannose/metabolism , Mycobacterium tuberculosis/metabolism , Th1 Cells/immunology , Animals , Dextran Sulfate , Disease Models, Animal , Humans , Immune Tolerance , Inflammatory Bowel Diseases/chemically induced , Lipopolysaccharides/immunology , Mannose/immunology , Mice , Mice, KnockoutABSTRACT
Neutralizing antibodies against human immunodeficiency virus subtype 1 (HIV-1) bind to its envelope glycoprotein (Env). Half of the molecular mass of Env is carbohydrate making it one of the most heavily glycosylated proteins known in nature. HIV-1 Env glycans are derived from the host and present a formidable challenge for host anti-glycan antibody induction. Anti-glycan antibody induction is challenging because anti-HIV-1 glycan antibodies should recognize Env antigen while not acquiring autoreactivity. Thus, the glycan network on HIV-1 Env is referred to as the glycan shield. Despite the challenges presented by immune recognition of host-derived glycans, neutralizing antibodies capable of binding the glycans on HIV-1 Env can be generated by the host immune system in the setting of HIV-1 infection. In particular, a cluster of high mannose glycans, including an N-linked glycan at position 332, form the high mannose patch and are targeted by a variety of broadly neutralizing antibodies. These high mannose patch-directed HIV-1 antibodies can be categorized into distinct categories based on their antibody paratope structure, neutralization activity, and glycan and peptide reactivity. Below we will compare and contrast each of these classes of HIV-1 glycan-dependent antibodies and describe vaccine design efforts to elicit each of these antibody types.
Subject(s)
Antibodies, Monoclonal/chemistry , Antibodies, Neutralizing/chemistry , Antibodies, Neutralizing/therapeutic use , Broadly Neutralizing Antibodies/chemistry , HIV Antibodies/chemistry , HIV Envelope Protein gp120/immunology , HIV-1/immunology , Mannose/immunology , Peptide Fragments/immunology , Polysaccharides/immunology , Animals , Antibodies, Monoclonal/metabolism , Antibodies, Monoclonal/therapeutic use , Antibodies, Neutralizing/genetics , Antibodies, Neutralizing/metabolism , Antibody Formation , Broadly Neutralizing Antibodies/metabolism , Broadly Neutralizing Antibodies/therapeutic use , Epitopes/metabolism , Glycosylation , HIV Antibodies/metabolism , HIV Antibodies/therapeutic use , HIV Infections/immunology , HIV Infections/metabolism , Humans , Immunogenicity, Vaccine , Polysaccharides/chemistryABSTRACT
SCOPE: Glycodendropeptides (GDPs) functionalized with mannose can enhance allergen interaction with dendritic cells (DCs) via C-type lectin receptors (CLRs), modulating the immune response. They can present multiple peptides and have potential applications for diagnosis and treatment of food allergy (FA). The immune response induced by GDPs with mannose and Pru p 3 peptides (mono/tetravalent) with ester (D1 ManPrup3/D4 ManPrup3) or ether linkers (D1 Man-O- Prup3/D4 Man-O- Prup3) in lipid-transfer-protein-allergic patients and tolerant controls is analyzed. METHODS AND RESULTS: The immunological response induced by GDPs is studied by assessing monocyte-derived-DC maturation, lymphocyte proliferation, cytokine production, and basophil response by flow cytometry. Dn ManPrup3 was recognized by DCs via CLRs inducing DC maturation in all subjects. However, CCR7 expression is significantly upregulated in allergic patients compared to tolerant controls. These changes correlate with lymphocyte proliferation and specific production of Th2/Th1 cytokines in allergic patients. Moreover, D1 ManPrup3 does not induce basophil activation. CONCLUSION: Dn ManPrup3 induces changes in DC maturation and lymphocyte proliferation, indicating specific recognition via CLRs. Prup3-GDPs are recognized by immune cells, inducing a specific immune response and modulating the immunological response in FA patients. The specific geometry of D1 ManPrup3 in particular makes it a potential candidate for specific immunotherapy development.
Subject(s)
Antigens, Plant/immunology , Carrier Proteins/immunology , Dendritic Cells/immunology , Food Hypersensitivity/etiology , Glycopeptides/immunology , Mannose/immunology , Plant Proteins/immunology , T-Lymphocytes/immunology , Adult , Basophils/physiology , Cytokines/biosynthesis , Female , Food Hypersensitivity/immunology , Humans , Lectins, C-Type/physiology , Lymphocyte Activation , Male , Middle AgedABSTRACT
Typical crystallizable fragment (Fc) glycans attached to the CH2 domain in therapeutic monoclonal antibodies (mAbs) are core-fucosylated and asialo-biantennary complex-type glycans, e.g., G2F (full galactosylation), G1aF (terminal galactosylation on the Man α1-6 arm), G1bF (terminal galactosylation on the Man α1-3 arm), and G0F (non-galactosylation). Terminal galactose (Gal) residues of Fc-glycans are known to influence effector functions such as antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity (CDC), but the impact of the G1F isomers (G1aF and G1bF) on the effector functions has not been reported. Here, we prepared four types of glycoengineered anti-CD20 mAbs bearing homogeneous G2F, G1aF, G1bF, or G0F (G2F mAb, G1aF mAb, G1bF mAb, or G0F mAb, respectively), and evaluated their biological activities. Interestingly, G1aF mAb showed higher C1q- and FcγR-binding activities, CDC activity, and FcγR-activation property than G1bF mAb. The activities of G1aF mAb and G1bF mAb were at the same level as G2F mAb and G0F mAb, respectively. Hydrogen-deuterium exchange/mass spectrometry analysis of dynamic structures of mAbs revealed the greater involvement of the terminal Gal residue on the Man α1-6 arm in the structural stability of the CH2 domain. Considering that mAbs interact with FcγR and C1q via their hinge proximal region in the CH2 domain, the structural stabilization of the CH2 domain by the terminal Gal residue on the Man α1-6 arm of Fc-glycans may be important for the effector functions of mAbs. To our knowledge, this is the first report showing the impact of G1F isomers on the effector functions and dynamic structure of mAbs. Abbreviations: ABC, ammonium bicarbonate solution; ACN, acetonitrile; ADCC, antibody-dependent cell-mediated cytotoxicity; C1q, complement component 1q; CDC, complement-dependent cytotoxicity; CQA, critical quality attribute; Endo, endo-ß-N-acetylglucosaminidase; FA, formic acid; Fc, crystallizable fragment; FcγR, Fcγ receptors; Fuc, fucose; Gal, galactose; GlcNAc, N-acetylglucosamine; GST, glutathione S-transferase; HER2, human epidermal growth factor receptor 2; HDX, hydrogen-deuterium exchange; HILIC, hydrophilic interaction liquid chromatography; HLB-SPE, hydrophilic-lipophilic balance-solid-phase extraction; HPLC, high-performance liquid chromatography; mAb, monoclonal antibody; Man, mannose; MS, mass spectrometry; PBS, phosphate-buffered saline; SGP, hen egg yolk sialylglycopeptides.
Subject(s)
Galactose/chemistry , Polysaccharides/chemistry , Rituximab/chemistry , Animals , Antibody-Dependent Cell Cytotoxicity/drug effects , Chickens/immunology , Fucose/chemistry , Fucose/immunology , Galactose/immunology , Glycosylation , Humans , Immunoglobulin Fc Fragments/chemistry , Mannose/chemistry , Mannose/immunology , Polysaccharides/immunology , Rituximab/metabolism , Rituximab/therapeutic useABSTRACT
d-Glycero-ß-d-manno-heptose 1,7-biphosphate (ß-HBP) is a novel microbial-associated molecular pattern that triggers inflammation and thus has the potential to act as an immune modulator in many therapeutic contexts. To better understand the structure-activity relationship of this molecule, we chemically synthesized analogs of ß-HBP and tested their ability to induce canonical TIFA-dependent inflammation in human embryonic kidney cells (HEK 293T) and colonic epithelial cells (HCT 116). Of the analogs tested, only d-glycero-ß-d-manno-heptose 1-phosphate (ß-HMP) induced TIFA-dependent NF-κB activation and cytokine production in a manner similar to ß-HBP. This finding expands the spectrum of metabolites from the Gram-negative ADP-heptose biosynthesis pathway that can function as innate immune agonists and provides a more readily available agonist of the TIFA-dependent inflammatory pathway that can be easily produced by synthetic methods.
Subject(s)
Gram-Negative Bacteria/physiology , Heptoses/immunology , Immunity, Innate , Immunologic Factors/immunology , Inflammation/immunology , Mannose/immunology , Pathogen-Associated Molecular Pattern Molecules/immunology , Phosphates/immunology , Pyrans/immunology , Adaptor Proteins, Signal Transducing/metabolism , HEK293 Cells , Heptoses/chemical synthesis , Humans , Immunization , Immunologic Factors/chemical synthesis , Inflammation/chemically induced , Mannose/chemical synthesis , Phosphates/chemical synthesis , Pyrans/chemical synthesis , Signal Transduction , Structure-Activity Relationship , Substrate SpecificityABSTRACT
Glucose-derived mannose is a common component of glycoproteins, and its deficiency leads to a severe defect in protein glycosylation and failure in basic cell functions. In this work, we show that mannose metabolism is essential for IFN-γ production by mouse Th1 cells. In addition, we demonstrate that the susceptibility of Th1 cells to glycolysis restriction depends on the activation conditions and that under diminished glycolytic flux, mannose availability becomes the limiting factor for IFN-γ expression. This study unravels a new role for glucose metabolism in the differentiation process of Th1 cells, providing a mechanistic explanation for the importance of glycolysis in immune cell functions.
Subject(s)
Cell Differentiation/immunology , Gene Expression Regulation/immunology , Glycolysis/immunology , Interferon-gamma/immunology , Mannose/immunology , Th1 Cells/immunology , Animals , Mice , Th1 Cells/cytologyABSTRACT
Mannose-capped lipoarabinomannan (ManLAM), present in all members of the Mycobacterium tuberculosis complex and in other pathogenic Mycobacterium spp, is a high molecular mass amphipathic lipoglycan with a defined critical role in mycobacterial survival during infection. In particular, ManLAM is well-characterized for its importance in providing M. tuberculosis a safe portal of entry to phagocytes, regulating the intracellular trafficking network, as well as immune responses of infected host cells. These ManLAM immunological characteristics are thought to be linked to the subtle but unique and well-defined structural characteristics of this molecule, including but not limited to the degree of acylation, the length of the D-mannan and D-arabinan cores, the length of the mannose caps, as well as the presence of other acidic constituents such as succinates, lactates and/or malates, and also the presence of 5-methylthioxylosyl. The impact of all these structural features on ManLAM spatial conformation and biological functions during M. tuberculosis infection is still uncertain. In this review, we dissect the relationship between ManLAM structure and biological function addressing how this relationship determines M. tuberculosis interactions with host cells, and how it aids this exceptional pathogen during the course of infection.
Subject(s)
Gene Expression Regulation/immunology , Host-Pathogen Interactions/immunology , Lipopolysaccharides/chemistry , Mannose/chemistry , Mycobacterium tuberculosis/chemistry , Tuberculosis, Pulmonary/immunology , Acylation , Carbohydrate Sequence , Humans , Immunity, Innate , Lectins, C-Type/genetics , Lectins, C-Type/immunology , Lipopolysaccharides/immunology , Mannose/immunology , Mannose Receptor , Mannose-Binding Lectins/genetics , Mannose-Binding Lectins/immunology , Microbial Viability , Mycobacterium tuberculosis/immunology , Mycobacterium tuberculosis/pathogenicity , Nod2 Signaling Adaptor Protein/genetics , Nod2 Signaling Adaptor Protein/immunology , Phagocytes/immunology , Phagocytes/microbiology , Receptors, Cell Surface/genetics , Receptors, Cell Surface/immunology , Receptors, Complement/genetics , Receptors, Complement/immunology , Toll-Like Receptors/genetics , Toll-Like Receptors/immunology , Tuberculosis, Pulmonary/genetics , Tuberculosis, Pulmonary/microbiologyABSTRACT
Tumor vaccines for cancer prevention and treatment have attracted tremendous interests in the area of cancer immunotherapy in recent years. In this work, we present a strategy to construct cancer vaccines by encapsulating immune-adjuvant nanoparticles with cancer cell membranes modified by mannose. Poly(d,l-lactide- co-glycolide) nanoparticles are first loaded with toll-like receptor 7 agonist, imiquimod (R837). Those adjuvant nanoparticles (NP-R) are then coated with cancer cell membranes (NP-R@M), whose surface proteins could act as tumor-specific antigens. With further modification with mannose moiety (NP-R@M-M), the obtained nanovaccine shows enhanced uptake by antigen presenting cells such as dendritic cells, which would then be stimulated to the maturation status to trigger antitumor immune responses. With great efficacy to delay tumor development as a prevention vaccine, vaccination with such NP-R@M-M in combination with checkpoint-blockade therapy further demonstrates outstanding therapeutic efficacy to treat established tumors. Therefore, our work presents an innovative way to fabricate cancer nanovaccines, which in principle may be applied for a wide range of tumor types.